COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.

ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.

COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.

COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701

Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.